SCM
CAPR icon

Suvretta Capital Management’s Capricor Therapeutics CAPR Stock Holding History

Suvretta Capital Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$98.6M Buy
4,092,784
+274,184
+7% +$8.31M 1.8% 19
2026
Q1 		$116M Buy
3,818,600
+2,032,990
+114% +$54.2M 2.97% 8
2025
Q4 		$51.5M Buy
+1,785,610
New +$23.3M 1.06% 36

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Suvretta Capital Management's CAPR Position: Q2 2026 in Review

Suvretta Capital Management increased its Capricor Therapeutics (CAPR) stake by 7.2% in Q2 2026, buying an estimated $8.31M and bringing the position to 4,092,784 shares worth $98.6M. The position accounts for 1.8% of the portfolio, ranked #19.

Suvretta Capital Management first reported a position in CAPR in Q4 2025 and has held it in 3 quarters since. The position peaked at $116M in Q1 2026. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Suvretta Capital Management held 4,092,784 shares of Capricor Therapeutics worth $98.6M as of Q2 2026.
  • Suvretta Capital Management bought 274,184 Capricor Therapeutics shares in Q2 2026, an estimated $8.31M.
  • Capricor Therapeutics made up 1.8% of Suvretta Capital Management's portfolio in Q2 2026, its #19 holding.
  • Suvretta Capital Management first reported a position in Capricor Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Suvretta Capital Management's Capricor Therapeutics position peaked at $116M in Q1 2026.
  • 170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Suvretta Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.